Kinnate Biopharma Inc Net Income per Employee (KNTE), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Kinnate Biopharma Inc   (NASDAQ: KNTE)
 

Kinnate Biopharma Inc Net Income per Employee

KNTE's Quarterly Results, Trends, Rankings, Statistics
Kinnate Biopharma Inc recorded a cumulative net loss of $-113 million during 12 month ending in the fourth quarter 2023.
The Healthcare sector has seen employees of 339 other companies achieving higher income per employee. While Kinnate Biopharma Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 4791.


What is Income per Employee Ratio?






KNTE Net Income per Employee (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,137,869 -1,284,384 -1,284,424 -1,235,444 -1,174,455
KNTE's Total Ranking # 4791 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


KNTE Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 340
Healthcare Sector # 810
Overall Market # 4791

Net Income per Employee Statistics
High Average Low
$ -216,616 $ -1,042,077 $ -1,284,424
(Jun 30 2021)   (Jun 30 2023)







Companies with similar Income per Employee for 12 month ending Dec 31 2023, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2023Number of Employees Dec 31 2023


Date modified: 2026-08-31T01:01:25+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.